Kinase Inhibitors Market Demand will reach a value of US$ 64.9 Billion by 2027 at a CAGR of 4% | Due to Increase in Incidence of Cancer Patients

According to the report, the global 𝗸𝗶𝗻𝗮𝘀𝗲 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 market was valued at ~US$ 46.4 Bn in 2018 and is projected to expand at a CAGR of ~4% from 2019 to 2027. Kinase inhibitors are available in various types including non-receptor tyrosine kinase inhibitors, receptor tyrosine kinase inhibitors, multikinase inhibitors, serine/threonine kinase inhibitors, protein kinase C inhibitors, RHO kinase inhibitors, and others. Various applications of kinase inhibitors include oncology, inflammatory diseases, and others. Growth of the global kinase inhibitors market can be attributed to rise in awareness about kinase inhibitors and surge in product approvals and increase in incidence of cancer across globe.

North America dominated the global kinase inhibitors market in 2018 and the trend is anticipated to continue during the forecast period. Rise in awareness about new drugs for treatment and availability of all major companies in the region are anticipated to drive the market in North America. Asia Pacific is expected to be a highly lucrative market for kinase inhibitors, expanding at a higher CAGR during the forecast period.

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗮 𝗦𝗮𝗺𝗽𝗹𝗲 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗮𝘁 (𝗨𝘀𝗲 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗠𝗮𝗶𝗹 𝗜𝗱 𝗳𝗼𝗿 𝗤𝘂𝗶𝗰𝗸 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲) - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=818

𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗶𝗻 𝗜𝗻𝗰𝗶𝗱𝗲𝗻𝗰𝗲 𝗼𝗳 𝗖𝗮𝗻𝗰𝗲𝗿, 𝗥𝗶𝘀𝗲 𝗶𝗻 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗮𝗯𝗼𝘂𝘁 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀, 𝗮𝗻𝗱 𝗦𝘂𝗿𝗴𝗲 𝗶𝗻 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀 𝘁𝗼 𝗗𝗿𝗶𝘃𝗲 𝗠𝗮𝗿𝗸𝗲𝘁

Cancer has a major impact on the society across the world. It is one of the leading causes of death across the globe and is more prevalent in developed and emerging markets. According to the American Cancer Society data, over 1.7 million new cancer cases are expected to be diagnosed in 2019 in the U.S. Awareness about cancer diagnosis and treatment is being spread across the globe. Governing bodies are also taking initiatives to provide access to health care to the public. Companies are taking initiatives to launch more products for the treatment. Intense drug discovery programs have led to the development of clinically effective kinase inhibitors. Since 2001, more than 10,000 patent applications for kinase inhibitors have been filed in the U.S. alone.

𝗡𝗼𝗻-𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗧𝘆𝗿𝗼𝘀𝗶𝗻𝗲 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝘁𝗼 𝗪𝗶𝘁𝗻𝗲𝘀𝘀 𝗛𝗶𝗴𝗵 𝗗𝗲𝗺𝗮𝗻𝗱

Based on type, the global kinase inhibitors market has been divided into non-receptor tyrosine kinase inhibitors, receptor tyrosine kinase inhibitors, multikinase inhibitors, serine/threonine kinase inhibitors, protein kinase C Inhibitors, RHO kinase inhibitors, and others. Non-receptor tyrosine kinase inhibitors is further segmented into Bruton's tyrosine kinase (BTK) inhibitors, BCR-ABL, Janus kinase (JAK) inhibitor, mesenchymal epithelial transition growth factor (c-MET), spleen tyrosine kinase (SYK) inhibitors, and others. The receptor tyrosine kinase inhibitors segment is again divided into VEGFR, PDGFR, EGFR, ALK, HER2, and others.

The non-receptor tyrosine kinase inhibitors segment dominated the global kinase inhibitors market in 2018 and the trend is likely to continue during the forecast period. Rise in approvals of different types of non-receptor tyrosine kinase inhibitors fuels the segment growth. In November 2019, FDA approved Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa) for patients with relapsed and refractory mantle cell lymphoma.

𝗕𝘂𝘆 𝘁𝗵𝗶𝘀 𝗣𝗿𝗲𝗺𝗶𝘂𝗺 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 | 𝗜𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗔𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗮𝘁 - https://www.transparencymarketresearch.com/checkout.php?rep_id=818<ype=S

𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝘁𝗼 𝗯𝗲 𝗞𝗲𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗔𝗿𝗲𝗮

In terms of application, the global kinase inhibitors market has been segmented into oncology, inflammatory diseases, and others. Oncology is further divided into lung cancer, renal cell cancer, breast cancer, and others. The oncology segment dominated the global kinase inhibitors market in 2018 and is expected to grow with the highest CAGR in the forecast period. Large number of approved drugs along with rich product pipeline for cancer treatment is anticipated to fuel the growth of the segment in the near future. Based on data from clinicaltrials.gov last updated on January 2020, over 75 kinase inhibitor drugs are in various phases of clinical trials for the application of oncology.

𝗥𝗶𝘀𝗲 𝗶𝗻 𝗡𝘂𝗺𝗯𝗲𝗿 𝗼𝗳 𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗶𝗲𝘀 𝘁𝗼 𝗗𝗿𝗶𝘃𝗲 𝗠𝗮𝗿𝗸𝗲𝘁

Based on distribution channel, the global kinase inhibitors market has been segmented into hospital pharmacies, independent pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global kinase inhibitors market in terms of revenue in 2018 and the trend is projected to continue during the forecast period. Increase in number of prescription-based kinase inhibitors being dispensed through independent pharmacies and rise in number of independent pharmacies in developing countries make these pharmacies a major channel of distribution.

𝗡𝗼𝗿𝘁𝗵 𝗔𝗺𝗲𝗿𝗶𝗰𝗮 𝘁𝗼 𝗗𝗼𝗺𝗶𝗻𝗮𝘁𝗲 𝗚𝗹𝗼𝗯𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁

Geographically, the global kinase inhibitors market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global kinase inhibitors market in 2018, followed by Europe. North America accounted for major share of the global kinase inhibitors market in 2018, owing to introduction of new drugs, and high prevalence of cases in countries such as the U.S. The kinase inhibitors market in Asia Pacific is likely to expand at a higher CAGR from 2019 to 2027. Significant growth of the kinase inhibitors market in the region can be attributed to high prevalence of cancers and increase in demand for its therapeutics.

𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝗼𝗻 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲

Novartis AG, Pfizer, Johnson & Johnson, AstraZeneca, and Bristol-Myers Squibb are the leading players in the global kinase inhibitors market that hold majority of the market share. The global kinase inhibitors Market is fragmented in terms of number of players. Key players in the global market include Novartis AG, Pfizer, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim International GmbH, Bayer AG, F. Hoffmann-La Roche Ltd, and Eisai Co., Ltd. New product development through robust R&D activities and merger & acquisitions are the key strategies adopted by these players to operate their business in the global kinase inhibitors market

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗗𝗶𝘀𝗰𝗼𝘂𝗻𝘁 𝗼𝗻 𝘁𝗵𝗶𝘀 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗮𝘁- https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=818

𝗚𝗹𝗼𝗯𝗮𝗹 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻

𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁, 𝗯𝘆 𝗧𝘆𝗽𝗲
𝗡𝗼𝗻-𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗧𝘆𝗿𝗼𝘀𝗶𝗻𝗲 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀
Bruton's Tyrosine Kinase (BTK) Inhibitors
BCR-ABL
Janus Kinase (JAK) Inhibitor
Mesenchymal Epithelial Transition Growth Factor (c-MET)
Spleen Tyrosine Kinase (SYK) Inhibitors
Others

𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗧𝘆𝗿𝗼𝘀𝗶𝗻𝗲 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀
VEGFR
PDGFR
EGFR
ALK
HER2
Others

𝗠𝘂𝗹𝘁𝗶𝗸𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀
𝗦𝗲𝗿𝗶𝗻𝗲/𝗧𝗵𝗿𝗲𝗼𝗻𝗶𝗻𝗲 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀
𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗞𝗶𝗻𝗮𝘀𝗲 𝗖 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀
𝗥𝗛𝗢 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀
𝗢𝘁𝗵𝗲𝗿𝘀

𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁, 𝗯𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻
𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆
Lung Cancer
Renal cell cancer
Breast Cancer
Others

𝗜𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗼𝗿𝘆 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀
Others

𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁, 𝗯𝘆 𝗗𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗖𝗵𝗮𝗻𝗻𝗲𝗹
Hospital Pharmacies
Independent Pharmacies
Online Pharmacies

𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁, 𝗯𝘆 𝗥𝗲𝗴𝗶𝗼𝗻
𝗡𝗼𝗿𝘁𝗵 𝗔𝗺𝗲𝗿𝗶𝗰𝗮
U.S.
Canada
𝗘𝘂𝗿𝗼𝗽𝗲
Germany
U.K.
France
Italy
Spain
Rest of Europe
𝗔𝘀𝗶𝗮 𝗣𝗮𝗰𝗶𝗳𝗶𝗰
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
𝗟𝗮𝘁𝗶𝗻 𝗔𝗺𝗲𝗿𝗶𝗰𝗮
Brazil
Mexico
Rest of Latin America
𝗠𝗶𝗱𝗱𝗹𝗲 𝗘𝗮𝘀𝘁 & 𝗔𝗳𝗿𝗶𝗰𝗮
GCC Countries
South Africa
Israel
Rest of Middle East & Africa

𝗠𝗼𝗿𝗲 𝗧𝗿𝗲𝗻𝗱𝗶𝗻𝗴 𝗥𝗲𝗽𝗼𝗿𝘁𝘀 𝗯𝘆 𝗧𝗿𝗮𝗻𝘀𝗽𝗮𝗿𝗲𝗻𝗰𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 -

𝗖𝗼𝗹𝗹𝗮𝗴𝗲𝗻 𝗣𝗲𝗽𝘁𝗶𝗱𝗲 & 𝗚𝗲𝗹𝗮𝘁𝗶𝗻 𝗠𝗮𝗿𝗸𝗲𝘁- https://www.accesswire.com/724980/Collagen-Peptide-Gelatin-Market-to-Exceed-Value-of-US-78-Bn-by-2031-States-TMR-Analysis

𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗠𝗢 𝗠𝗮𝗿𝗸𝗲𝘁- https://www.prnewswire.com/news-releases/asia-pacific-records-highest-cagr-of-17-8-in-healthcare-cmo-market-over-2013-2019--tmr-study-301695614.html

𝗔𝗯𝗼𝘂𝘁 𝗨𝘀 𝗧𝗿𝗮𝗻𝘀𝗽𝗮𝗿𝗲𝗻𝗰𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝘀

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.